A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
Conditions: Chronic Obstructive Pulmonary Disease; Lung Non-Small Cell Carcinoma; Pneumonia; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...